Health Care · Biological Products, (No Diagnostic Substances)

INBX Inhibrx Biosciences, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 200791952 filings
Russell 2000

INBX at a glance

Inhibrx Biosciences, Inc. (INBX, SEC CIK 2007919) filed its latest 10-K annual report on March 19, 2026, a 10-Q quarterly report on November 13, 2026, an 8-K current report on November 17, 2026 and Form 4 insider filings as recently as October 14, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Inhibrx Biosciences, Inc. (INBX) reported revenue of $1.3 million (up 550.0% from FY2024) and a net loss of $140.1 million. Diluted EPS was -$9.04.
  • As of September 30, 2026, 23 institutional investment managers tracked by SignalX reported holding Inhibrx Biosciences, Inc. (INBX) shares worth $528.9 million in 13F-HR filings.
  • The most recent insider open-market purchase reported on Form 4 was by Lappe Mark on October 14, 2026 of 2,470 shares at $84.07 per share.
  • In the last 90 days, INBX insiders reported 20 open-market purchases ($6.3M) and 5 open-market sales ($279K) on Form 4, a net purchase of $6.1M.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$1.3M
+550.0% vs prior year
Insiders · 90 days
20 buys · 5 sells
Net +$6.1M
13F holders
23 funds
$528.9M · −1 vs prior quarter
Latest 8-K
Nov 17, 2026
Item 8.01

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Revenue $2.0M, versus $0 in Q3 2025, entirely from Pfizer license fee revenue
  • Net loss $38.7M versus $35.3M, operating loss $31.7M versus $33.8M
  • R&D expense $26.0M, down 9% YoY, while G&A rose to $7.8M from $5.3M
  • Cash $199.5M at September 30, 2026, with $177.8M financing inflows including $175.0M debt proceeds
  • Outlook: cash sufficient for at least 12 months, but continued losses and higher clinical, manufacturing, and pre-commercialization spending expected

Risk Factors

  • Newly added regulatory risk: BIOSECURE Act restricts U.S. government dealings involving designated biotechnology companies of concern
  • Most materially updated manufacturing risk: FDA Form 483 observations at both ozekibart contract manufacturers threaten BLA approval
  • Clinical risk: Ozekibart BLA may face a Complete Response Letter if manufacturers fail to resolve inspection findings
  • Operational risk: Limited third-party manufacturers and no long-term supply agreements increase supply disruption exposure
  • Market risk: Unbuilt commercialization infrastructure could impair ozekibart launch execution and reimbursement uptake

AI summary of the INBX 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 17, 2026Full analysis →

Item 8.01: Other Events

  • Updated clinical data for ozekibart, or INBRX-109, in relapsed or refractory Ewing sarcoma
  • Phase 1/2 expansion study evaluates ozekibart combined with irinotecan and temozolomide

Item EX-99.1: Item EX-99.1

  • Updated Phase 1/2 Ewing sarcoma data: 62.7% ORR and 86.3% DCR among 51 response-evaluable patients
  • Responses included 2 complete responses and 30 partial responses, with 18 patients achieving benefit exceeding 6 months
Filed Nov 13, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Inhibrx announced financial results for the three and nine months ended September 30, 2026
  • Full financial figures and management commentary are in Exhibit 99.1, the accompanying earnings release

Item EX-99.1: Item EX-99.1

  • Q3 2026 net loss $38.7M, or $2.46 per share, versus $35.3M, or $2.28, in Q3 2025
  • Cash $199.5M, while long-term debt rose to $276.7M from $100.6M at December 31, 2025
Filed Sep 28, 2026Full analysis →

Item 7.01: Regulation FD Disclosure

  • Updated corporate presentation posted September 28, 2026, signaling refreshed investor messaging
  • Presentation likely summarizes current business updates for conferences and investor meetings

AI summaries of INBX 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for INBX

Don't miss the next INBX filing

  • Alerts as it files. A push when INBX files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut INBX, by share count.
  • Ask anything. An AI agent that reads every INBX filing and answers with sources.

INBX alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Lappe MarkBuyOct 14, 2026$84.07
Lappe MarkBuyOct 14, 2026$84.07
Lappe MarkBuyOct 14, 2026$85.00
Lappe MarkBuyOct 14, 2026$85.76
Lappe MarkBuyOct 14, 2026$85.00
Lappe MarkBuyOct 14, 2026$85.76
Lappe MarkBuySep 28, 2026$98.88
Lappe MarkBuySep 28, 2026$101.70

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue$1.8M$200K$1.3M
Operating Income--$331.4M-$135.0M
Net Income-$1.7B-$140.1M
Op. Margin--165724.0%-10386.5%
Net Margin-843786.0%-10773.5%
Balance Sheet
Total Assets$307.9M$180.8M$146.5M
Equity$43.5M$133.6M$8.0M
ROE-1263.3%-1752.2%
Per Share
EPS$-20.48$112.62$-9.04
Cash Flow
Operating CF--$194.4M-$129.8M
CapEx-$2.6M$31K

Source: XBRL data in Inhibrx Biosciences, Inc. (INBX)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate INBX share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
INBX shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202623$528.9M
Q2 202624$586.8M
Q1 202626$373.0M
Q4 202523$448.1M
Q3 202522$147.5M
Q2 202517$55.4M
Q1 202516$43.8M
Q4 202412$47.5M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers

Source: 13F-HR filings on SEC EDGAR (aggregated from 163 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

INBX filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
8-KNov 17, 2026Analysis-
8-KNov 13, 2026Analysis-
10-QNov 13, 2026Analysis
4Oct 14, 2026--
8-KSep 28, 2026Analysis-
4Sep 28, 2026--
4Sep 23, 2026--
4Sep 18, 2026--
4Sep 18, 2026--
4Sep 18, 2026--
4Sep 18, 2026--
4Sep 17, 2026--
4Sep 15, 2026--
4Sep 10, 2026--
8-KSep 8, 2026Analysis-
4Sep 8, 2026--
4Sep 8, 2026--
4Sep 8, 2026--
SC 13GAug 14, 2026-
8-KAug 13, 2026Analysis-
10-QAug 13, 2026Analysis
SC 13GAug 3, 2026-
8-KJul 16, 2026Analysis-
8-KJun 15, 2026Analysis-
4Jun 4, 2026-

Related Health Care companies

All Health Care →

INBX SEC filings: frequently asked questions

Are INBX insiders buying or selling?

In the last 90 days, Inhibrx Biosciences, Inc. (INBX) officers, directors and 10% owners reported 20 open-market purchases worth $6.3 million by 3 insiders and 5 open-market sales worth $279,010 by 1 insider on Form 4, a net purchase of $6.1 million. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold INBX stock?

As of September 30, 2026, the largest Inhibrx Biosciences, Inc. (INBX) holders among the 13F filers tracked by SignalX were Morgan Stanley ($132.2 million), Viking Global Investors ($110.9 million), BlackRock ($82.3 million), State Street Corp ($56.6 million), Vanguard Capital Management LLC ($53.8 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was INBX's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Inhibrx Biosciences, Inc. (INBX) reported revenue of $1.3 million (up 550.0% from FY2024) and a net loss of $140.1 million. Diluted EPS was -$9.04. The figures come from the XBRL data in the 10-K.

What did INBX report in its latest 8-K?

Inhibrx Biosciences, Inc. (INBX) filed an 8-K on November 17, 2026 reporting Item 8.01 (Other Events). Updated clinical data for ozekibart, or INBRX-109, in relapsed or refractory Ewing sarcoma.

What are the latest INBX SEC filings?

Inhibrx Biosciences, Inc. (INBX) filed its latest 10-K annual report on March 19, 2026, a 10-Q quarterly report on November 13, 2026, an 8-K current report on November 17, 2026 and a Form 4 insider filing on October 14, 2026.

What is INBX's SEC CIK number?

Inhibrx Biosciences, Inc. (INBX)'s SEC Central Index Key (CIK) is 2007919. EDGAR lists every INBX filing under that number.

Ask anything about INBX

The research agent reads INBX's filings, financials, insider trades and 13F holders, then answers with sources.